Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601469 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02601469: Completed Phase 2 study of Plaque Psoriasis, sponsored by Sun Pharmaceutical Industries.
NCT02601469 is a Phase 2 study of Plaque Psoriasis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 26 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02601469, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
Primary Outcome
Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or presence of adrenal suppression at the end of treatment. HPA Axis suppression is defined as a 30 minute post CortrosynTM injection level cortisol level of ≤ 18 mcg/100ml.
Conditions Studied
Interventions
- DRUG DSXS
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-09-04 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 2 |
What the finished NCT02601469 record still lists
NCT02601469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DSXS is the first listed.
NCT02601469 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02601469 about?
NCT02601469 is a clinical study titled "Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis". An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT02601469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2015-09-04. Estimated completion is 2017-08-25.
What conditions does trial NCT02601469 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02601469?
The interventions under investigation include: DSXS (DRUG).
Who is sponsoring clinical trial NCT02601469?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02601469 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02601469's enrollment target sits among peer trials
26 40th of 45 higher than 6 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI